Ctrl

K

Abrocitinib

Class
Targeted therapy
Subclass
Janus kinase inhibitors
Generic name
Abrocitinib
Brand names
Cibinqo®
Common formulations
Film-coated tablet
Dosage and administration
Adults patients
Treatment of atopic dermatitis • Refractory, moderate-to-severe
•
Maintenance: 100 mg PO daily
•
Maximum: 200 mg per day
Indications for use
Labeled indications
Adults
•
Treatment of atopic dermatitis (refractory, moderate-to-severe)
Adverse reactions
Very common > 10%
•
Infections, nasopharyngitis, nausea
Common 1-10%
•
Acne, contact dermatitis, ↓ blood lymphocyte count, ↓ platelet count, gastroenteritis, herpes simplex virus infection, herpes zoster, hypertension, impetigo, ↑ serum CK, influenza, abdominal discomfort, dizziness, epigastric abdominal pain, fatigue, headache, throat pain, vomiting, urinary tract infections
Uncommon < 1%
•
Carcinogenesis, deep venous thrombosis, hyperlipidemia, pulmonary embolism, retinal detachment
Unknown frequency
•
Arterial thrombosis, cerebrovascular accident, hepatitis exacerbation, myocardial infarction, sudden cardiac death
Interactions
Drug(s)
Check Interactions
Reset

What did you think about this content?

Create free account

Sign up for free to access the full drug resource